about
Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells.Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells.The expression sequence tag is an effective method for screening DNA segments that predict urinary bladder transitional cell carcinoma prognosis.Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy.Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer.Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma.Prostatectomy using different lasers for the treatment of benign prostate hyperplasia in aging malesTopoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells.Celastrol blocks interleukin-6 gene expression via downregulation of NF-κB in prostate carcinoma cellsWNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer.Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cellsPTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo.The Correlation between Chitin and Acidic Mammalian Chitinase in Animal Models of Allergic Asthma.The Vitamin D Analog, MART-10, Attenuates Triple Negative Breast Cancer Cells Metastatic PotentialMechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells.Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo.25(OH)D Is Effective to Repress Human Cholangiocarcinoma Cell Growth through the Conversion of 25(OH)D to 1α,25(OH)₂D₃Is diabetes mellitus associated with clinical outcomes in aging males treated with transurethral resection of prostate for bladder outlet obstruction: implications from Taiwan Nationwide Population-Based Cohort StudyThioredoxin-interacting protein: an oxidative stress-related gene is upregulated by glucose in human prostate carcinoma cells.Transurethral resection of the prostate achieves favorable outcomes in stroke patients with symptomatic benign prostate hyperplasia.GPR56/ADGRG1 Activation Promotes Melanoma Cell Migration via NTF Dissociation and CTF-Mediated Gα12/13/RhoA Signaling.The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.MART-10, a newly synthesized vitamin D analog, represses metastatic potential of head and neck squamous carcinoma cells.Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells.MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential.Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells.Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.N-myc downstream-regulated gene 1 downregulates cell proliferation, invasiveness, and tumorigenesis in human oral squamous cell carcinoma.The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells.MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells.Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells.Cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived Ets factor.Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2.Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells.Testosterone modulates mitochondrial aconitase in the full-length human androgen receptor-transfected PC-3 prostatic carcinoma cells.
P50
Q33827212-8616570B-3F0D-47D6-A895-ACAB8391067FQ34124640-83E13740-26F1-4FF1-A7A0-C4046D742C7DQ34346935-26AD0A78-1815-4DED-B9EA-B6606CBA2276Q34352787-17368EE0-AA99-4891-9020-366A59CB157EQ34415314-559B7256-C0DC-430E-AE65-054055BA4F04Q34758084-39861A35-D835-4ACC-9EEA-A0660940E445Q34904867-02C03F9C-6A5D-48E3-BA2E-2D7706A30BA0Q35047389-94F0C930-CCBF-4E52-9B9A-FCF3370D55B2Q35106686-CC908AF1-3070-44A2-91A0-AD498A0CB1B9Q35130330-7B96870F-8252-4C7B-AE95-D23566062710Q35138841-92F88E72-AA92-4732-B149-92A33CC0F83FQ35926034-E42D725C-392D-4CF8-9381-717D37E6E50AQ35970618-C9DD503D-6B50-4A13-9C89-DA5E31BA6450Q36324716-003505CE-D54A-42BE-ADAC-CBE3066B2A03Q36847293-414B1915-0B45-400C-B8C9-FAB869B1F311Q36898645-C596BBF9-C9DD-41F9-9FCB-9A39F2BA355BQ36906268-4E1E785D-DA1D-49A5-8AB4-32DBCE5B0822Q37210157-2D467B1D-C0F2-4EF0-B5BE-09E4B2FDCB81Q37714109-68B0DFDD-F092-430C-90B4-92A6261A1EB6Q38358453-BC328971-CF98-46F6-9576-FE26D5F38A41Q38649444-C92FE4F9-7524-43FA-88AF-12B962E99CBDQ38732606-B1F31151-2DC0-43E4-8EED-CBA077DD0757Q38748533-0B6A8C82-79E5-4169-8123-417CE2B74DA5Q38759640-E0C5048A-B0BB-4DA8-BC48-4FD44071BBCCQ38787159-8596335D-F6C3-4A56-B01E-E26B5C599A30Q38843014-45E71A05-5FC2-4F0A-8049-5330C0AA0059Q38905697-948CB7E2-6BAA-4C79-922F-739F4EA850DAQ38923071-33EDDA39-AF22-4342-AE87-BA2885373819Q38956823-3F35F436-A4DB-4B50-942D-4463C0D42CB9Q38963621-DD45352D-A1E1-4BC3-9511-B2BEA91079DAQ39094656-A94750C5-B30D-45AD-B3C4-ABBCF1123816Q39437475-5A6EACE9-A1FD-46EA-828C-A4D02DFF5E4CQ39470443-58BDBF8B-5EF7-4F33-8F17-D73BB28B1155Q39502702-4AF0E189-180B-4ED6-A81F-476F09759BCDQ39635634-D0EF5D9B-9F1F-4A40-B293-1DFF7B3587FEQ39654369-C00B6283-4AB5-42A1-B627-F1146D76B85EQ39954581-F196BA77-2C42-4C28-AEC6-D3B8F568F377Q40024999-E7A8A8FA-B1FF-4385-8C65-C5B20F6B64E0Q40428033-0230DBD6-15A5-488C-AB2D-549BDBB5251DQ40529083-C61C2711-3FDA-49EF-8D94-3ED7FB329003
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Horng-Heng Juang
@ast
Horng-Heng Juang
@en
Horng-Heng Juang
@es
Horng-Heng Juang
@nl
Horng-Heng Juang
@sl
type
label
Horng-Heng Juang
@ast
Horng-Heng Juang
@en
Horng-Heng Juang
@es
Horng-Heng Juang
@nl
Horng-Heng Juang
@sl
prefLabel
Horng-Heng Juang
@ast
Horng-Heng Juang
@en
Horng-Heng Juang
@es
Horng-Heng Juang
@nl
Horng-Heng Juang
@sl
P1053
G-2313-2012
P106
P1153
7007039834
P31
P3829
P496
0000-0002-8524-8253